tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Sutro Biopharma regains compliance with Nasdaq
PremiumThe FlySutro Biopharma regains compliance with Nasdaq
3M ago
Sutro Biopharma price target raised to $51 from $5 at Deutsche Bank
Premium
The Fly
Sutro Biopharma price target raised to $51 from $5 at Deutsche Bank
3M ago
Sutro Biopharma’s Promising Phase 1 Study on STRO-004: A Potential Game-Changer in Cancer Treatment
Premium
Company Announcements
Sutro Biopharma’s Promising Phase 1 Study on STRO-004: A Potential Game-Changer in Cancer Treatment
3M ago
Sutro Biopharma announces 1-for-10 reverse stock split
PremiumThe FlySutro Biopharma announces 1-for-10 reverse stock split
3M ago
Sutro Biopharma: Balancing Innovation with Caution Amid Strategic and Clinical Uncertainties
Premium
Ratings
Sutro Biopharma: Balancing Innovation with Caution Amid Strategic and Clinical Uncertainties
4M ago
Sutro Biopharma: Sell Rating Amid Preclinical Data and Uncertain Clinical Prospects
Premium
Ratings
Sutro Biopharma: Sell Rating Amid Preclinical Data and Uncertain Clinical Prospects
4M ago
Sutro Biopharma’s STRO-002: A Promising Phase 1 Trial Update in Ovarian and Endometrial Cancers
PremiumCompany AnnouncementsSutro Biopharma’s STRO-002: A Promising Phase 1 Trial Update in Ovarian and Endometrial Cancers
7M ago
Sutro Biopharma price target lowered to $3 from $4 at Wells Fargo
Premium
The Fly
Sutro Biopharma price target lowered to $3 from $4 at Wells Fargo
7M ago
Sutro Biopharma’s Strategic Shift and Pipeline Developments: A Hold Rating Amid Transitional Phase
Premium
Ratings
Sutro Biopharma’s Strategic Shift and Pipeline Developments: A Hold Rating Amid Transitional Phase
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100